| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Net income | -4.8 | -3.0 |
| EPS (diluted, $ a share) | $-0.09 | $-0.47 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
10-Q filed with the SEC, NASDAQ: APRE. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Aprea Therapeutics, Inc.: key numbers
- Share price
- $0.4063Close, Nov 16
- Market cap
- $5.77M
- Shares outstanding
- 14.19MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Aprea Therapeutics, Inc.
All →Aprea Therapeutics Financial Results
Aprea Therapeutics reported third quarter 2026 financial results and provided a clinical update on its oral WEE1 inhibitor, APR-1051. The company expanded its Phase 1 clinical trial network to nine sites and expects to select a dose for the optimization phase of the study in the first half of 2027.
“We continue to make meaningful progress in advancing APR-1051 towards our goal of developing a differentiated, potentially best-in-class WEE1 inhibitor for patients with biomarker defined cancers.”
Oren Gilad, Ph.D., President and Chief Executive Officer
“With $37.8 million in cash and cash equivalents as of September 30, 2026, and an expected cash runway into the first quarter of 2028, we believe we are well positioned to execute our clinical development strategy, achieve meaningful milestones, and create long-term value for patients and shareholders.”
Oren Gilad, Ph.D., President and Chief Executive Officer